Discover 1,917 paid clinical trials in Arlington, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,917
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
for
Metastatic Castration-resistant Prostate Cancer
Location: Arlington TX, Dallas TX, Tyler TX, Oklahoma City OK,
Sponsor: Amgen
Sex: Male
Age: 18+
Code: NCT07213674
Phase3, Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
for
Non-Muscle Invasive Bladder Neoplasms
Location: Arlington TX, Dallas TX, Little Rock AR, St Louis MO,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07309445
Recruiting
Ambulatory Long Length URodynamics Evaluation
for
Urology, Urinary Bladder, Overactive,
Location: Arlington TX, New Orleans LA, St Louis MO,
Sponsor: Bright Uro
Sex: All
Age: 22+
Code: NCT07425015
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
for
Bladder (Urothelial, Transitional Cell) Cancer,
Location: Arlington TX, Houston TX, Little Rock AR, St Louis MO,
Sponsor: Protara Therapeutics
Sex: All
Age: 18+
Code: NCT07480356
Phase3, Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
for
Melanoma
Location: Bedford TX, Fort Worth TX, Grapevine TX, Dallas TX,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06246916
Phase3, Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)